Latest news
IPM Brief – Issue 13 | The Test Is Becoming the Politics
By Denis Horgan
FSHD Gets a Stronger Biological Signal
ALS Immunotherapy Moves Into the Extension Phase
Measles Deaths in England Expose the Cost of Missed Protection
Europe’s AMR Strategy Depends on the Lab Result Being Right
Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
AMR Stewardship Starts Before the Antibiotic Is Prescribed
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.